Top Industry Leaders in the Wound Care Biologics Market
Latest Wound Care Biologics Companies Updates:
TideLines Medical (TSX: TLMD): Launched Artacent AC, a tri-layer skin graft designed for use in complex or difficult-to-treat wounds.
MiMedX Group (NSDQ: MDXG): Received FDA approval for PURION® processed Dehydrated Human Amnion/Chorion Membrane (dHACM) for promoting healing in acute partial-thickness burns.
Organogenesis (NASDAQ: ORGO): Announced the availability of PuraPly® Plus, a new bioabsorbable collagen matrix with additional hyaluronic acid for improved moisture retention and healing in chronic wounds.
Regenerative Biotherapeutics (OTCQB: RGBP): Initiated a Phase 2a clinical trial evaluating their investigational cell therapy, RBX2660, for treating diabetic foot ulcers.
Stemcell Technologies (TSX: SCII): Participating in a clinical trial to identify potential biomarkers for personalized treatment of chronic wounds using GABA levels in the blood.
List of Wound Care Biologics companies in the market:
- Smith & Nephew (UK)
- Wright Medical (US)
- Mölnlycke Health Care AB (Sweden)
- MiMedx Group (US)
- Vericel Corporation (US)
- Anika Therapeutics (US)
- Osiris Therapeutics (US)
- Marine Polymer Technologies, Inc. (US)
- Kerecis (Iceland)
- Solsys Medical (US)
- ACell (US)